Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yoshimi Muta"'
Autor:
Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiroshi Takeda, Hisashi Yokomizo, Kei Takeshita, Keiichi Chin, Keizo Kanasaki, Kouichi Tamura, Masaaki Miyauchi, Masuo Saburi, Miwa Morita, Miwako Yomota, Moritsugu Kimura, Nobuo Hatori, Shinichi Nakajima, Shun Ito, Shunichiro Tsukamoto, Takashi Murata, Takaya Matsushita, Takayuki Furuki, Takuya Hashimoto, Tomoya Umezono, Yuichi Takashi, Daiji Kawanami
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients
Externí odkaz:
https://doaj.org/article/e387d4d5ba7242e08853f9abf1debf8d
Autor:
Yuichi Takashi, Kyoko Toyokawa, Naoki Oda, Yoshimi Muta, Hisashi Yokomizo, Seiji Fukumoto, Daiji Kawanami
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
IntroductionX-linked hypophosphatemia (XLH) is the most prevalent type of heritable fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets. Recently, anti-FGF23 antibody, burosumab, has become clinically available. We herein report a pa
Externí odkaz:
https://doaj.org/article/ab92c8ce2f354df88e32ba7ea54d1bbf
Autor:
Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under di
Externí odkaz:
https://doaj.org/article/155ed996fcd945919dc2998e13d7c2f0
Autor:
Yoshimi Muta, Tomoko Tanaka, Yuriko Hamaguchi, Nobuya Hamanoue, Ryoko Motonaga, Makito Tanabe, Takashi Nomiyama, Hajime Nawata, Toshihiko Yanase
Publikováno v:
Biochemistry and Biophysics Reports, Vol 17, Iss , Pp 177-181 (2019)
We previously identified a novel selective androgen receptor modulator, S42, that does not stimulate prostate growth but has a beneficial effect on lipid metabolism. S42 also increased muscle weight of the levator ani in orchiectomized Sprague–Dawl
Externí odkaz:
https://doaj.org/article/c9e5a62f62084d79bb857204a1edd468